vs
Side-by-side financial comparison of ONESPAWORLD HOLDINGS Ltd (OSW) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $242.1M, roughly 1.2× ONESPAWORLD HOLDINGS Ltd). Bio-Techne runs the higher net margin — 12.8% vs 5.0%, a 7.9% gap on every dollar of revenue. On growth, ONESPAWORLD HOLDINGS Ltd posted the faster year-over-year revenue change (11.5% vs -6.4%). Over the past eight quarters, ONESPAWORLD HOLDINGS Ltd's revenue compounded faster (7.1% CAGR vs 4.2%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
OSW vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $242.1M | $295.9M |
| Net Profit | $12.1M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 6.8% | 18.4% |
| Net Margin | 5.0% | 12.8% |
| Revenue YoY | 11.5% | -6.4% |
| Net Profit YoY | -16.2% | 68.3% |
| EPS (diluted) | $0.12 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $242.1M | $295.9M | ||
| Q3 25 | $258.5M | — | ||
| Q2 25 | $240.7M | $317.0M | ||
| Q1 25 | $219.6M | $316.2M | ||
| Q4 24 | $217.2M | $297.0M | ||
| Q3 24 | $241.7M | $289.5M | ||
| Q2 24 | $224.9M | $306.1M | ||
| Q1 24 | $211.2M | $303.4M |
| Q4 25 | $12.1M | $38.0M | ||
| Q3 25 | $24.3M | — | ||
| Q2 25 | $19.9M | $-17.7M | ||
| Q1 25 | $15.3M | $22.6M | ||
| Q4 24 | $14.4M | $34.9M | ||
| Q3 24 | $21.6M | $33.6M | ||
| Q2 24 | $15.8M | $40.6M | ||
| Q1 24 | $21.2M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | 6.8% | 18.4% | ||
| Q3 25 | 10.2% | — | ||
| Q2 25 | 9.2% | -7.5% | ||
| Q1 25 | 7.7% | 12.2% | ||
| Q4 24 | 7.9% | 16.0% | ||
| Q3 24 | 10.3% | 13.8% | ||
| Q2 24 | 8.4% | 15.0% | ||
| Q1 24 | 8.0% | 22.1% |
| Q4 25 | 5.0% | 12.8% | ||
| Q3 25 | 9.4% | — | ||
| Q2 25 | 8.3% | -5.6% | ||
| Q1 25 | 7.0% | 7.1% | ||
| Q4 24 | 6.6% | 11.7% | ||
| Q3 24 | 8.9% | 11.6% | ||
| Q2 24 | 7.0% | 13.3% | ||
| Q1 24 | 10.0% | 16.2% |
| Q4 25 | $0.12 | $0.24 | ||
| Q3 25 | $0.23 | — | ||
| Q2 25 | $0.19 | $-0.11 | ||
| Q1 25 | $0.15 | $0.14 | ||
| Q4 24 | $0.13 | $0.22 | ||
| Q3 24 | $0.20 | $0.21 | ||
| Q2 24 | $0.15 | $0.26 | ||
| Q1 24 | $0.21 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.3M | $172.9M |
| Total DebtLower is stronger | $84.0M | $260.0M |
| Stockholders' EquityBook value | $542.6M | $2.0B |
| Total Assets | $707.1M | $2.5B |
| Debt / EquityLower = less leverage | 0.15× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $172.9M | ||
| Q3 25 | $29.6M | — | ||
| Q2 25 | $35.0M | $162.2M | ||
| Q1 25 | $22.6M | $140.7M | ||
| Q4 24 | $57.4M | $177.5M | ||
| Q3 24 | $48.8M | $187.5M | ||
| Q2 24 | $62.5M | $152.9M | ||
| Q1 24 | $65.4M | $145.3M |
| Q4 25 | $84.0M | $260.0M | ||
| Q3 25 | $85.2M | — | ||
| Q2 25 | $96.2M | $346.0M | ||
| Q1 25 | $97.4M | $330.0M | ||
| Q4 24 | $98.6M | $300.0M | ||
| Q3 24 | $98.7M | $300.0M | ||
| Q2 24 | $123.8M | $319.0M | ||
| Q1 24 | $138.6M | $389.0M |
| Q4 25 | $542.6M | $2.0B | ||
| Q3 25 | $552.8M | — | ||
| Q2 25 | $548.3M | $1.9B | ||
| Q1 25 | $530.6M | $2.0B | ||
| Q4 24 | $554.5M | $2.1B | ||
| Q3 24 | $540.1M | $2.1B | ||
| Q2 24 | $532.7M | $2.1B | ||
| Q1 24 | $515.5M | $2.0B |
| Q4 25 | $707.1M | $2.5B | ||
| Q3 25 | $732.6M | — | ||
| Q2 25 | $731.8M | $2.6B | ||
| Q1 25 | $708.7M | $2.6B | ||
| Q4 24 | $746.4M | $2.7B | ||
| Q3 24 | $734.0M | $2.7B | ||
| Q2 24 | $756.8M | $2.7B | ||
| Q1 24 | $763.6M | $2.7B |
| Q4 25 | 0.15× | 0.13× | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.18× | 0.18× | ||
| Q1 25 | 0.18× | 0.16× | ||
| Q4 24 | 0.18× | 0.14× | ||
| Q3 24 | 0.18× | 0.14× | ||
| Q2 24 | 0.23× | 0.15× | ||
| Q1 24 | 0.27× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.0M | — |
| Free Cash FlowOCF − Capex | $14.9M | — |
| FCF MarginFCF / Revenue | 6.2% | — |
| Capex IntensityCapex / Revenue | 2.1% | — |
| Cash ConversionOCF / Net Profit | 1.65× | — |
| TTM Free Cash FlowTrailing 4 quarters | $68.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.0M | — | ||
| Q3 25 | $33.2M | — | ||
| Q2 25 | $20.3M | $98.2M | ||
| Q1 25 | $10.1M | $41.1M | ||
| Q4 24 | $16.6M | $84.3M | ||
| Q3 24 | $28.6M | $63.9M | ||
| Q2 24 | $18.7M | $75.5M | ||
| Q1 24 | $15.0M | $81.0M |
| Q4 25 | $14.9M | — | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $17.6M | $93.3M | ||
| Q1 25 | $8.4M | $31.0M | ||
| Q4 24 | $13.2M | $77.5M | ||
| Q3 24 | $27.5M | $54.7M | ||
| Q2 24 | $17.6M | $57.5M | ||
| Q1 24 | $13.7M | $64.5M |
| Q4 25 | 6.2% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 7.3% | 29.4% | ||
| Q1 25 | 3.8% | 9.8% | ||
| Q4 24 | 6.1% | 26.1% | ||
| Q3 24 | 11.4% | 18.9% | ||
| Q2 24 | 7.8% | 18.8% | ||
| Q1 24 | 6.5% | 21.3% |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 0.8% | 3.2% | ||
| Q4 24 | 1.5% | 2.3% | ||
| Q3 24 | 0.5% | 3.2% | ||
| Q2 24 | 0.5% | 5.9% | ||
| Q1 24 | 0.6% | 5.4% |
| Q4 25 | 1.65× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.02× | — | ||
| Q1 25 | 0.66× | 1.82× | ||
| Q4 24 | 1.15× | 2.42× | ||
| Q3 24 | 1.33× | 1.90× | ||
| Q2 24 | 1.19× | 1.86× | ||
| Q1 24 | 0.71× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
